Literature DB >> 16049305

Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays.

Lynne V Abruzzo1, Jing Wang, Mini Kapoor, L Jeffrey Medeiros, Michael J Keating, W Edward Highsmith, Lynn L Barron, Candy C Cromwell, Kevin R Coombes.   

Abstract

Oligonucleotide microarrays are a powerful tool for profiling the expression levels of thousands of genes. Different statistical methods for identifying differentially expressed genes can yield different results. To our knowledge, no experimental test has been performed to decide which method best identifies genes that are truly differentially expressed. We applied three statistical methods (dChip, t-test on log-transformed data, and Wilcoxon test) to identify differentially expressed genes in previously untreated patients with chronic lymphocytic leukemia (CLL). We used a training set of Affymetrix Hu133A microarray data from 11 patients with unmutated immunoglobulin (Ig) heavy chain variable region (VH) genes and 8 patients with mutated Ig VH genes. Differential expression was validated using semiquantitative real-time polymerase chain reaction assays and by validating models to predict the somatic mutation status of an independent test set of nine CLL samples. The methods identified 144 genes that were differentially expressed between cases of CLL with unmutated compared with mutated Ig VH genes. Eighty genes were identified by Wilcoxon test, 60 by t-test, and 65 by dChip, but only 11 were identified by all three methods. Greater agreement was found between the t-test and the Wilcoxon test. Differential expression was validated by semiquantitative real-time polymerase chain reaction assays for 83% of individual genes, regardless of the statistical method. However, the Wilcoxon test gave the most accurate predictions on new samples, and dChip, the least accurate. We found that all three methods were equally good for finding differentially expressed genes, but they found different genes. The genes selected by the nonparametric Wilcoxon test are the most robust for predicting the status of new cases. A comprehensive list of all differentially expressed genes can only be obtained by combining the results of multiple statistical tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049305      PMCID: PMC1867538          DOI: 10.1016/s1525-1578(10)60562-4

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  25 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Identifying differentially expressed genes in cDNA microarray experiments.

Authors:  K A Baggerly; K R Coombes; K R Hess; D N Stivers; L V Abruzzo; W Zhang
Journal:  J Comput Biol       Date:  2001       Impact factor: 1.479

3.  A model for measurement error for gene expression arrays.

Authors:  D M Rocke; B Durbin
Journal:  J Comput Biol       Date:  2001       Impact factor: 1.479

4.  Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site.

Authors:  Rossana Zaru; Thomas O Cameron; Lawrence J Stern; Sabina Müller; Salvatore Valitutti
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

5.  Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.

Authors:  Christian Korz; Armin Pscherer; Axel Benner; Daniel Mertens; Claudia Schaffner; Elke Leupolt; Hartmut Döhner; Stephan Stilgenbauer; Peter Lichter
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

6.  Identification and characterization of DPZF, a novel human BTB/POZ zinc finger protein sharing homology to BCL-6.

Authors:  W Zhang; J Mi; N Li; L Sui; T Wan; J Zhang; T Chen; X Cao
Journal:  Biochem Biophys Res Commun       Date:  2001-04-13       Impact factor: 3.575

7.  Empirical bayes methods and false discovery rates for microarrays.

Authors:  Bradley Efron; Robert Tibshirani
Journal:  Genet Epidemiol       Date:  2002-06       Impact factor: 2.135

8.  BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence.

Authors:  C R Kovac; A Emelyanov; M Singh; N Ashouian; B K Birshtein
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

9.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

10.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application.

Authors:  C Li; W Hung Wong
Journal:  Genome Biol       Date:  2001-08-03       Impact factor: 13.583

View more
  4 in total

1.  Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays.

Authors:  Ann L Oberg; Neelam Dhiman; Diane E Grill; Jenna E Ryan; Richard B Kennedy; Gregory A Poland
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

2.  Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.

Authors:  Lynne V Abruzzo; Lynn L Barron; Keith Anderson; Rachel J Newman; William G Wierda; Susan O'brien; Alessandra Ferrajoli; Madan Luthra; Sameer Talwalkar; Rajyalakshmi Luthra; Dan Jones; Michael J Keating; Kevin R Coombes
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

3.  A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Lixia Diao; Rachel J Newman; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; Rajyalakshmi Luthra; L Jeffrey Medeiros; Michael J Keating; Lynne V Abruzzo
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq.

Authors:  Anto P Rajkumar; Per Qvist; Ross Lazarus; Francesco Lescai; Jia Ju; Mette Nyegaard; Ole Mors; Anders D Børglum; Qibin Li; Jane H Christensen
Journal:  BMC Genomics       Date:  2015-07-25       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.